Breast Cancer Genome Guided Therapy Study (BEAUTY) (BEAUTY)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02022202 |
Recruitment Status
:
Active, not recruiting
First Posted
: December 27, 2013
Last Update Posted
: February 6, 2018
|
Tracking Information | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date | December 20, 2013 | |||||||||
First Posted Date | December 27, 2013 | |||||||||
Last Update Posted Date | February 6, 2018 | |||||||||
Actual Study Start Date | February 2013 | |||||||||
Estimated Primary Completion Date | December 2018 (Final data collection date for primary outcome measure) | |||||||||
Current Primary Outcome Measures |
|
|||||||||
Original Primary Outcome Measures | Same as current | |||||||||
Change History | Complete list of historical versions of study NCT02022202 on ClinicalTrials.gov Archive Site | |||||||||
Current Secondary Outcome Measures |
99mTc-sestamibi uptake and pathologic response following neoadjuvant chemotherapy. [ Time Frame: 5 years ] Assess the association between changes in 99mTc-sestamibi uptake and pathologic response following neoadjuvant chemotherapy (MCR participants only).
|
|||||||||
Original Secondary Outcome Measures | Same as current | |||||||||
Current Other Outcome Measures | Not Provided | |||||||||
Original Other Outcome Measures | Not Provided | |||||||||
Descriptive Information | ||||||||||
Brief Title | Breast Cancer Genome Guided Therapy Study (BEAUTY) | |||||||||
Official Title | Breast Cancer Genome Guided Therapy Study (BEAUTY) | |||||||||
Brief Summary | The purpose of this research study is to better understand the reasons why or why not breast cancers are destroyed by standard chemotherapy. This information will be used to develop new and better cancer therapies. | |||||||||
Detailed Description | Not Provided | |||||||||
Study Type | Observational | |||||||||
Study Design | Observational Model: Case-Only Time Perspective: Prospective |
|||||||||
Target Follow-Up Duration | Not Provided | |||||||||
Biospecimen | Retention: Samples With DNA Description: Breast cancer tissue and blood specimens |
|||||||||
Sampling Method | Probability Sample | |||||||||
Study Population | Primary Care Clinic | |||||||||
Condition | Invasive Breast Cancer | |||||||||
Intervention | Not Provided | |||||||||
Study Groups/Cohorts | Not Provided | |||||||||
Publications * | Not Provided | |||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||||||||
Recruitment Information | ||||||||||
Recruitment Status | Active, not recruiting | |||||||||
Estimated Enrollment |
200 | |||||||||
Original Estimated Enrollment | Same as current | |||||||||
Estimated Study Completion Date | December 2018 | |||||||||
Estimated Primary Completion Date | December 2018 (Final data collection date for primary outcome measure) | |||||||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
|||||||||
Sex/Gender |
|
|||||||||
Ages | 18 Years to 99 Years (Adult, Senior) | |||||||||
Accepts Healthy Volunteers | No | |||||||||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||||||||
Listed Location Countries | United States | |||||||||
Removed Location Countries | ||||||||||
Administrative Information | ||||||||||
NCT Number | NCT02022202 | |||||||||
Other Study ID Numbers | MC1137 | |||||||||
Has Data Monitoring Committee | Yes | |||||||||
U.S. FDA-regulated Product | Not Provided | |||||||||
IPD Sharing Statement | Not Provided | |||||||||
Responsible Party | Mayo Clinic | |||||||||
Study Sponsor | Mayo Clinic | |||||||||
Collaborators | Not Provided | |||||||||
Investigators |
|
|||||||||
PRS Account | Mayo Clinic | |||||||||
Verification Date | February 2018 |